Lite Strategy, Inc. (LITS) vs Rani Therapeutics Holdings, Inc. (RANI)

A side-by-side comparison of Lite Strategy, Inc. and Rani Therapeutics Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

LITS

Lite Strategy, Inc.

$48M

$1.41HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

RANI

Rani Therapeutics Holdings, Inc.

$54M

$0.83HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — LITS vs RANI

growth of $100 · dividends reinvested · last 1y

LITS -69.1% (-69.1%/yr)RANI +66.3% (+66.3%/yr)RANI compounded faster over this window

Log scale — wide-divergence pair

LITS RANI

LITS vs RANI: by the numbers

•RANI is the larger company ($54M vs $48M market cap).
•Both run net losses; LITS's is the smaller (0.00% vs -618.02% net margin).

Metrics side by side

Valuation

Metric	LITS	RANI
P/S ratio	N/A	11.10
P/B ratio	1.15	1.38

Profitability

Metric	LITS	RANI
Gross margin	0.00%	44.89%
Operating margin	0.00%	-2345.99%
Net margin	0.00%	-618.02%
ROE	-170.94%	-76.82%
ROIC	-30.75%	-63.96%

Growth (annualized)

Metric	LITS	RANI
Revenue CAGR (5Y)	N/A	9.95%
Total return CAGR (5Y)	N/A	-46.70%

Go deeper

Full LITS analysis Full RANI analysis Interactive comparison tool

Dig into the metrics

Lite Strategy ROE Rani Therapeutics ROE Lite Strategy operating margin Rani Therapeutics operating margin Lite Strategy revenue growth Rani Therapeutics revenue growth Lite Strategy free cash flow Rani Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.